Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Dermatology | Immunology | Pulmonary/Respiratory Diseases

View By:YearCompanyConditionsTherapeutic AreasDrug Names

Dynabac

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Sanofi-aventis
Approval Status: Approved March 1998
Treatment Area: acute bacterial exacerbations

General Information

Dynabac, a member of the newer macrolide group of antibiotics, has received approval for expanded coverage within certain indications, including the treatment of acute bacterial exacerbations of chronic bronchitis and uncomplicated skin and skin structure infections. Dynabac remains a once-a-day therapy.

Side Effects

The most common side effects were gastrointestinal, including abdominal pain, nausea, and diarrhea.